The immune profile of small HER2-positive breast cancers: a secondary analysis from the APT trial.

ABSTRACT:

Background

Previous data suggest that the immune microenvironment plays a critical role in human epidermal growth factor receptor 2 (HER2) -positive breast cancer; however, there is little known about the immune profiles of small HER2-positive tumors. In this study, we aimed to characterize the immune microenvironment of small HER2-positive breast cancers included in the Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer (APT) trial and to correlate the immune markers with pathological and molecular tumor characteristics.

Patients and methods

The APT trial was a multicenter, single-arm, phase II study of paclitaxel and trastuzumab in patients with node-negative HER2-positive breast cancer. The study included 406 patients with HER2-positive, no

SUBMITTER: Barroso-Sousa R 

PROVIDER: S-EPMC8033534 | biostudies-literature | 2019 Apr

REPOSITORIES: biostudies-literature